An IRB, short for institutional review board, is a group that reviews human research to protect the people taking part. It can require changes or stop a study. Its approval concerns the research plan, not proof that a treatment works or permission to sell it.

What is an IRB under U.S. rules?

The Food and Drug Administration (FDA) defines an IRB as a group formally assigned to review and monitor human studies. Its questions and answers, dated “February 2025,” explain three options: approve a study, require changes before approval, or reject it.

The board reviews a protocol, the written plan for a particular study. It doesn't approve a molecule for every possible use.

Why ethics review exists

Research asks people to accept uncertainty so that researchers can learn something. The people taking that risk need someone looking after their rights, even when the study's goal sounds worthwhile.

The World Medical Association's 2024 Declaration of Helsinki, also published in JAMA, calls for independent ethics review before research begins. It puts participants' rights ahead of the pursuit of knowledge.

That declaration is an international statement of ethical principles. It isn't itself U.S. law. FDA rules apply to covered product studies. The Department of Health and Human Services (HHS) has separate rules for covered research, including HHS-supported work. Some studies fall under both.

What IRB language means around MOTS-c

MOTS-c is a peptide, a short chain of protein building blocks, studied for how the body handles fuel. A public registry is a database of study records. A listing can explain what researchers intend to test. It cannot establish what the treatment actually does.

As of November 5, 2026, the day this article was written, the MOTS-MET registry record lists recruiting status and no posted results. Its last posted update is dated April 1, 2026. The record names a study site in China and says the study is not FDA-regulated drug research.

The public record doesn't provide an ethics committee's approval letter. An American registry number therefore doesn't establish U.S. IRB review. The MOTS-c research update covers the study itself; the distinction here is between a public study plan and documented oversight.

Neither establishes outcomes for a pharmacy-made MOTS-c preparation prescribed after an individual visit.

What does an IRB actually check?

Under 21 CFR Part 56, the FDA's IRB rules, a board needs at least five members with different backgrounds. At least one focuses on science and one on nonscientific concerns. At least one must be unaffiliated with the institution, with no immediate family ties to anyone affiliated with it. A member with a conflicting interest cannot review that study, except to provide requested information.

The board looks at how the study will treat people, including:

  • Risks: whether avoidable risks have been reduced and remaining risks are reasonable for the expected benefit or knowledge.
  • Who joins: whether participants are selected fairly and people vulnerable to pressure have added safeguards.
  • Informed consent: how people learn what participation involves and agree freely.
  • Privacy: how personal information will be protected.
  • Safety monitoring: how researchers will watch for harm and respond to problems.

Scientific design matters too. A poorly planned study can expose people to risk without producing useful answers. Ethical review considers that problem; it doesn't predict a favorable result.

What an older DSIP study can tell us

DSIP means delta sleep-inducing peptide. Its early sleep experiments show why an oversight question and a treatment question need separate answers.

In Bes and colleagues' 1992 study in Neuropsychobiology, 16 people with chronic insomnia received DSIP or an inactive comparison treatment. The abstract describes weak effects and no change in participants' reported sleep quality. The DSIP benefits guide covers those findings in context.

The abstract doesn't identify an ethics committee. That omission doesn't establish that oversight was absent. Identifying the reviewing committee requires the study's ethics documentation. Even documented review would leave the study's weak results unchanged; it wouldn't establish benefit for a current pharmacy-made DSIP preparation.

Why review continues after a study starts

Oversight continues after the first decision. Researchers report changes and unexpected problems; a board can suspend or end its approval when requirements aren't followed or unexpected serious harm occurs.

As of November 5, 2026, the day this article was written, FDA rules require continuing review at least yearly, based on risk. The HHS Common Rule, the federal framework for covered human research, has exceptions for certain lower-risk and follow-up activities.

Three mistakes people make about IRB approval

“IRB approval means the drug passed FDA review.” IRB approval is not FDA approval. The board evaluates a study's participant protections. FDA marketing review examines the full application for a particular drug and intended use. One decision doesn't replace the other.

“An approved study must be safe.” Review asks whether the proposed risks are acceptable and managed. It cannot remove unknown risks or promise that nobody will be harmed. New information can change whether a study should continue.

“The approval follows the peptide.” A decision concerns a specific study plan and its conditions. It doesn't endorse every clinic, pharmacy, dose or product using the same ingredient. A letter for one MOTS-c study wouldn't establish review of another preparation.

What this means for a peptide prescription

A routine prescription is a care decision. It doesn't enroll someone in a study or create IRB oversight. That distinction matters when MOTS-c research appears beside a prescription product.

Through Promise, MOTS-c and DSIP are dispensed by a licensed U.S. compounding pharmacy as compounded medications, prepared for a prescription. These formulations are not FDA-approved. A licensed provider may still prescribe — that decision is between you and your doctor.

At Promise, a licensed provider reviews every request, and not everyone qualifies. That clinical review and a research board's review have different jobs.

An IND, or Investigational New Drug application, is the filing supporting a covered U.S. drug investigation. It addresses whether that investigation may proceed. IRB review addresses protections for its participants. A registry listing publicly records a study's plan and status; it doesn't substitute for either review.

The phases of clinical trials describe the questions researchers are asking as testing develops. Participant protections remain relevant across those stages, including studies after a medicine reaches the market.

Together, the records answer different questions: what is being studied, how participants are protected, and what the results actually show. A positive answer to one doesn't supply the others.